Dec. 22 at 7:49 AM
$PYXS At
$1.26, the company is trading very close to its Net Cash Value. With the 46% Monotherapy ORR (Efficacy is clearly there), 71% Combination ORR (Efficacy is elite), and a "Fixable" Toxicity Problem,
$1.26 is likely a price driven by panic and year-end tax selling, not by the long-term potential of the drug. If this drug had 10% efficacy and high toxicity,
$1.26 would be "fair." But because drug works extremely well (46-71% response vs. ~15-20% standard of care), the market is likely being far too emotional.
